The treatment of elderly patients with chronic lymphocytic leukemia and comorbid conditions requires an assessment of individual patient factors an......READ MORE
by Matthew S. Davids, MD, MMSc; Susan O'Brien, MD; and William G. Wierda, MD, PhD
The availability of targeted agents has changed the paradigm for the frontline treatment of patients with chronic lymphocytic leukemia (CLL), inclu......READ MORE
by Matthew S. Davids, MD, MMSc; Susan O'Brien, MD; and William G. Wierda, MD, PhD
The introduction of newer targeted therapies translates into more treatment options for patients with previously treated chronic lymphocytic leukem......READ MORE
Several prognostic markers are critically important to obtain prior to initiating therapy for treatment-naive chronic lymphocytic leukemia, and som......READ MORE
Individuals with chronic lymphocytic leukemia (CLL) have different concerns and priorities regarding their treatment. With all of the CLL treatment......READ MORE
Novel agent triplet regimens have shown early promise in clinical trials and have the potential to induce durable remissions in the frontline setti......READ MORE
